EP3230311A1 - Gène de fusion synthétique universel soluble améliorant l'adcc et technologie peptidique et son utilisation - Google Patents

Gène de fusion synthétique universel soluble améliorant l'adcc et technologie peptidique et son utilisation

Info

Publication number
EP3230311A1
EP3230311A1 EP15867381.4A EP15867381A EP3230311A1 EP 3230311 A1 EP3230311 A1 EP 3230311A1 EP 15867381 A EP15867381 A EP 15867381A EP 3230311 A1 EP3230311 A1 EP 3230311A1
Authority
EP
European Patent Office
Prior art keywords
cells
adcc
affinity
enhancer
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15867381.4A
Other languages
German (de)
English (en)
Other versions
EP3230311A4 (fr
EP3230311B1 (fr
Inventor
Chiang J. Li
Shyam UNNIRAMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
1Globe Biomedical Co Ltd
Original Assignee
1Globe Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1Globe Biomedical Co Ltd filed Critical 1Globe Biomedical Co Ltd
Publication of EP3230311A1 publication Critical patent/EP3230311A1/fr
Publication of EP3230311A4 publication Critical patent/EP3230311A4/fr
Application granted granted Critical
Publication of EP3230311B1 publication Critical patent/EP3230311B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Definitions

  • the invention relates to synthetic biology products and processes that can be used to enable immune effector cells, particularly, T cells, to mediate antibody-dependent cellular cytotoxicity (ADCC) as well as methods of using them in the treatment and prevention of cancer, infectious diseases, inflammatory and autoimmune diseases and other diseases.
  • ADCC antibody-dependent cellular cytotoxicity
  • Mammals especially higher vertebrates including human, have developed highly complex immune systems that use multiple mechanisms and effectors to detect, destroy, or at least contain foreign pathogens as well as diseased or stressed autologous cells. These diseased cells may have been infected by virus or bacteria, or have become cancerous.
  • cytotoxicity is through cell-mediated cytotoxicity, which can be carried out by a number of leukocytes and proteins.
  • cytotoxic effectors include: from the lymphoid lineage—Natural Killer (NK) cells and cytotoxic T lymphocytes (CTLs); and from the myeloid lineage— macrophages, neutrophils and eosinophils.
  • mAbs are a result of their bifunctional nature.
  • One end of an antibody (Fab) can be made extraordinarly specific to a particular tumor protein without altering the other end (Fc) which recruits a variety of effector cells and proteins that kill the tumor cell.
  • ADCC antibody-dependent cellular cytotoxicity
  • ADCC is primarily mediated by natural killer (NK) cells (and, to a lesser extent, neutrophils, monocytes and macrophages) that express a relatively low-affinity Fc receptor (FcyRIIIa, also known as CD 16a) that is only activated upon its binding with the Fc fragments of antibodies coating a multivalent antigen on a target diseased cell (e.g., a tumor cell).
  • NK natural killer
  • FcyRIIIa also known as CD 16a
  • This binding triggers the release of cytotoxic granules like perforin and granzyme (as well as many cytokines including IFN- ⁇ ), leading to the lysis of the target cell.
  • cytotoxic granules like perforin and granzyme (as well as many cytokines including IFN- ⁇ ), leading to the lysis of the target cell.
  • F158 lower affinity variant of CD16 have worse clinical outcomes.
  • ADCC efficacy as primarily mediated by endogenous natural killer (NK) cells, is limited in the body due to a number of physiological as well as pathological reasons as explained below (to the extent that endogenous Cytotoxic T lymphocytes participate in tumor clearance at all, their efficacy have also been found to be very limited and lacking).
  • NK natural killer
  • ADCC ADCC-associated cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic factor, cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic cytoplasmic
  • ADCC effector cells also express inhibitory receptors that dampen their immune responsiveness, thereby instituting a system of balances and checks.
  • These receptors include inhibitory KIRs (killer immunoglobulin-like receptors) for CD56 low K cells, FcyRIIb on monocytes and B cells, and CTLA-4 (CD 152) and PD- 1 (Programmed-Death-1, CD279) for T cells.
  • KIRs killer immunoglobulin-like receptors
  • FcyRIIb on monocytes and B cells
  • CTLA-4 CD 152
  • PD- 1 Programmed-Death-1, CD279
  • FcyRIIIa CD 16a
  • FcyRIIIa CD 16a
  • mAbs monoclonal antibodies
  • the present invention ushers in new approaches to improve the immune system's defense against cancer, infections and other diseases.
  • the present invention devises a novel, free-associating, Adapter-like ADCC Enhancer that couples the cytotoxicity and proliferative potential of T cells to antibody -based therapy.
  • a fusion protein is provided as a free- associating and circulating adapter that brings an antibody targeting a diseased cell (e.g., a tumor cell) into contact with CD3 + T cells.
  • This new adapter molecule is soluble and can be injected into the blood of the patient to access most tissue compartments.
  • This Adapter-like ADCC Enhancer has two components as follows: (a) a high-affinity Fc- binding domain; and (b) a high-affinity CD3-binding domain. The rationale for this approach is: this Adapter-like ADCC Enhancer will bind to a tumor cell already coated with one or more therapeutic antibodies, and the Enhancer can also bind to CD3 + T cells. Once in close proximity or in contact with a T cell, the antibodies that coat the tumor cell will cause crosslinking of the CD3s on the surface of T cell and lead to activation of the T cell and, eventually, lysis of the tumor cell.
  • the ADCC Enhancer of the present invention can be used either in combination with an antibody therapy or by itself to target diseased cells recognized or bound by a naturally occurring antibody.
  • the present invention sets out to build high-affinity Fc receptors or antibody fragments, such as those with higher affinity for a natural antibody than wildtype human CD16 (e.g., the most common form of human CD16, i.e., the common F 158 variant).
  • the Receptor hereinafter used as a term to encompass embodiments resembling more traditional cell-surface receptor and embodiments based on antibody fragment(s)), in part or in whole, may be borrowed from another
  • a high-affinity CD3 -binding domain is fused to the high-affinity Fc-binding domain or Receptor described in the first aspect.
  • high-affinity CD3- binding domains include OKT3 and novel anti-CD3 scFv.
  • the high-affinity Fc-binding domain in various embodiments, may be selected from the group consisting of the ectodomain of CD64, a high-affinity CD 16 variant, and an antibody fragment with high- affinity for human Fc.
  • the invention provides a pharmaceutical composition that includes the fusion protein of the invention which, in turn, comprises a high-affinity Fc-binding domain, and a high-affinity CD3 -binding domain.
  • the pharmaceutical composition further includes a pharmaceutically acceptable excipient.
  • the invention provides a method of treating a subject in need thereof for a condition therapeutically, said method comprising administering to said subject a therapeutically effective amount of the pharmaceutical composition of the invention.
  • the method may further include a step of administering a therapeutic antibody against at least one cell-surface antigen indicative of said condition.
  • the antibody comprises an Fc region substantially similar to the human IgG4.
  • the condition being treated may be a cancer, an inflammatory disease, an autoimmune disease, transplant rejection and an infection, and so on.
  • the invention provides a method of treating a subject in need thereof for similar conditions prophylactically, said method comprising administering to said subject a prophylactically effective amount of the pharmaceutical composition of the invention.
  • the method may further include a step of administering a vaccine against said condition.
  • the condition is a cancer.
  • Figure 1 schematically depicts an Adapter-like ADCC Enhancer according to the present invention.
  • FIG. 2 schematically depicts the exons of CD64 and CD 16.
  • CD64 has an additional immunoglobulin fold, and hence, exon, in the extracellular region. This additional fold is credited for CD64's higher Fc-affinity.
  • Figure 3 lists the amino acid sequence (SEQ ID NO: 1) for the Fc-binding domain of the Adapter-like ADCC Enhancer according to an embodiment of the present invention. Specifically, the domain in this embodiment includes the ectodomain of CD64 based on exon boundaries.
  • Figure 4 lists the amino acid sequence (SEQ ID NO:2) for the anti-CD3 domain of the Adapter-like ADCC Enhancer according to an embodiment of the present invention.
  • the domain in this embodiment includes two spacer/linker sequences (underlined) and a humanized version of OKT3 sequence.
  • Figure 5 lists the amino acid sequence (SEQ ID NO:3) for the entire amino acid sequence (SEQ ID NO:3) for the entire amino acid sequence (SEQ ID NO:3) for the entire amino acid sequence (SEQ ID NO:3) for the entire amino acid sequence (SEQ ID NO:3) for the entire amino acid sequence (SEQ ID NO:3) for the entire amino acid sequence (SEQ ID NO:3) for the entire amino acid sequence (SEQ ID NO:3) for the entire amino acid sequence (SEQ ID NO:3) for the entire amino acid sequence (SEQ ID NO:3) for the entire amino acid sequence (SEQ ID NO:3) for the entire amino acid sequence (SEQ ID NO:3) for the entire amino acid sequence (SEQ ID NO:3) for the entire amino acid sequence (SEQ ID NO:3) for the entire amino acid sequence (SEQ ID NO:3) for the entire amino acid sequence (SEQ ID NO:3) for the entire amino acid sequence (SEQ ID NO:3) for the entire amino acid sequence (SEQ ID NO:3) for the entire amino acid sequence (SEQ ID NO:3) for the entire amino acid sequence
  • Figure 6 lists a DNA sequence (SEQ ID NO: 4) for the entire Adapter-like
  • ADCC Enhancer according to the embodiment represented in FIG. 5.
  • Figure 7 is a photographic image of an immunoblot (western blot) showing time course of overexpression of two versions of the soluble, Adapter-like ADCC Enhancer in Expi293 cells. Both versions had the same CD64-OKT3 fusion protein sequence and only differ in their respective nucleotide sequences (Lanes 1 and 2). The protein was secreted into the media. Predicted molecular weight was 58 kDa; the anti-CD64 antibody picked a band at 75 kDa probably due to glycosylation.
  • Figure 8 are photographic images of coomasie-stained gels that illustrate purification of soluble ADCC Enhancer using a commercial human IgG column (GE Life Sciences). Transfected cells were completely removed from the culture supernatant through multiple centrifugation steps followed by ultrafiltration. The column was equilibrated in a neutral buffer and the supernatant was loaded, followed by the flow- through (to ensure complete binding). The protein was purified through a step-wise gradient of decreasing pH. The purified protein was immediately neutralized in high molarity alkaline Tris buffer. The purified protein was exchanged into PBS either by sequential dialysis or by repeated ultrafiltration through an Amicon® Ultra Centrifugal filters. Lanes in the gel on the right side represent various elution fractions when the washing buffer is at pH 3.05.
  • Figure 9 schematically depicts an assay using Jurkat cells to test the ability of an Adapter-like ADCC Enhancer of the present invention to bind CD3 + immune effector cells.
  • FIG. 10 illustrates FACS data showing, in an assay according to FIG. 9, the binding between Jurkat cells and the ADCC Enhancer of the invention before purification ("Sample Load”) and after purification ("Purified Protein”).
  • the unfilled curve represents the negative control.
  • purified ADCC Enhancer is used at 10-20 ng/microliter unless noted otherwise.
  • Figure 11 illustrates FACS data showing titration of binding between
  • FIG. 12 schematically depicts an assay using Daudi cells to test the ability of an Adapter-like ADCC Enhancer of the present invention to bind CD20 + target cells coated with Rituxan.
  • Figure 13 illustrates FACS data showing, in an assay according to
  • FIG. 12 the binding between Daudi cells and the ADCC Enhancer of the invention before purification ("Sample Load") and after purification ("Purified Protein”).
  • Figure 14 illustrates FACS data showing titration of binding between
  • Daudi cells and the ADCC Enhancer of the invention at various concentrations.
  • the volume of the Enhancer in microliters are indicated in the upper right corner of the top six diagrams as: 50, 25, 12.5, 6.25, 3.13 and 1.56 microliters.
  • the bottom diagram summarizes the data.
  • CD20 + Daudi cells were coated with Rituxan (anti-CD20 antibody) and excess Rituxan was removed by washing the cells with PBS.
  • Rituxan-coated cells were incubated with various amounts of the Enhancer, and excess Enhancer was removed by washing the cells in PBS.
  • Bound Enhancer proteins were detected using fluorescent anti-human CD64 antibody. There was approximately 30-fold higher affinity for the antibody observed in the ADCC Enhancer compared to CD20.
  • Figure 15 schematically depicts an assay using Daudi cells coated with Rituxan, and CD8 + T cells to test the ability of an Adapter-like ADCC Enhancer of the present invention to mediate and amplify cytotoxicity against target cancer cells.
  • FIG. 16 illustrates FACS data showing detection of the target (Daudi) cells (top cluster) and the effector T cells (bottom cluster), in an assay according to FIG. 15.
  • the data indicates that the Enhancer of the invention was able to recruit the T cells to lyse much of the Daudi cell population without diminishing T cell viability (right diagram).
  • E:T (effector cell to target cell) ratio was 10.
  • Figure 17 illustrates data from cytotoxicity experiments involving two concentrations of Rituxan (anti-CD20), CD20 + Daudi cells, CD8 + T cells and the Enhancer of the invention.
  • the data shows that the Enhancer increased T cell's killing of the target cells, and that the killing was dependent on both Rituxan and Enhancer concentrations.
  • Rituxan was used at 0.1 ⁇ g/ml (lOx) or 0.01 ⁇ g /ml (lx).
  • Enhancer was used at 12.5 microliter (+) or 50 microliter (+++).
  • Figure 18 illustrates data from cytotoxicity experiments involving two concentrations of Rituxan, Raji cells, CD8 + T cells and the Enhancer of the invention. The data shows similar results as in FIG. 17 at the same concentrations of Rituxan and Enhancer.
  • Figure 19 illustrates data from cytotoxicity experiments involving two concentrations of Herceptin, HER + SK-BR3 cells, CD8 + T cells and the Enhancer of the invention. The data shows even more pronounced cytotoxic effect (compared to results in FIG. 18) when the Enhancer was added.
  • Herceptin was used at 1 ⁇ g /ml (lOx) or 0.1 ⁇ g /ml (lx).
  • Enhancer was used at 50 microliter (+++).
  • Figure 20 schematically depicts how HER2 expression was measured in different breast cancer cells according to an example of the invention.
  • Figure 21 compares HER2 expression levels among three different breast cancer lines: MDA-MB-231, MCF7, and SK-BR3.
  • the far left peak represents unstained control, followed by peaks of MDA-MB-231, MCF7, and SK-BR3 cells, respectively.
  • the data shows that among the three, SK-BR3 has the highest HER2 expression level while MDA-MB-231 has the lowest.
  • Figure 22 illustrates data from cytotoxicity experiments involving
  • Herceptin, HER-hi SK-BR3 cells, HER-lo MDA-MB-231 cells, and the Enhancer of the invention show the Enhancer's ability to amplify Herceptin' s killing capacity in both types of breast cancer cells.
  • the data also shows more marked effect in SK-BR3 cells, indicating that the effect is dependent on the expression level of HER2.
  • the ability to kill MDA-MB-231 cells shows that the Enhancer of the invention can be used to sensitize even low HER2-expressing tumors to Herceptin. Enhancer was used at 50 microliter in these experiments.
  • Figure 23 illustrates data from cytotoxicity experiments involving
  • Nivolumab anti-PDl
  • HEK-293T cells that have transgenically expressed PD1
  • CD8 + T cells CD8 + T cells
  • the parental, unmodified HEK- 293T cells 293T
  • IgG4 control were included as controls.
  • Significant target cell lysis was seen only when cells expressing PD-1 were exposed to Nivolumab in the presence of the Enhancer.
  • CD8 + T cells were in all the samples depicted including the far left control.
  • a or “an” may mean one or more.
  • the words “a” or “an” may mean one or more than one.
  • another may mean at least a second or more.
  • “about” refers to a numeric value, including, for example, whole numbers, fractions, and percentages, whether or not explicitly indicated.
  • the term “about” generally refers to a range of numerical values (e.g., +/-5-10% of the recited value) that one of ordinary skill in the art would consider equivalent to the recited value (e.g., having the same function or result). In some instances, the term “about” may include numerical values that are rounded to the nearest significant figure.
  • antibody or "Ab”, as used herein, broadly refers to any immunoglobulin (Ig) molecule comprised of four polypeptide chains, two heavy (H) chains and two light (L) chains, or any functional fragment, mutant, variant, or derivation thereof, which retains the essential epitope binding features of an Ig molecule.
  • Such mutant, variant, or derivative antibody formats are known in the art, and include but are not limited to a single-chain Fv(scFv), Fab, F(ab'), F(ab') 2 , a single domain, and the like. Non-limiting embodiments of which are discussed below.
  • CD 16 is expressed as two distinct forms, CD 16a and CD 16b, which are products of two different yet highly homologous genes.
  • CD 16a is a polypeptide-anchored transmembrane protein while CD 16b is a glycosylphosphatidylinositol-anchored protein.
  • CD 16 refers to both forms of the protein, unless inappropriate as would be apparent to one skilled artisan.
  • Effector cells useful in practicing the present invention may be autologous, syngeneic or allogeneic, with the selection dependent upon the disease to be treated and means available.
  • the present invention discloses the Soluble Universal ADCC Enhancer
  • the enhancing mechanisms can include at least the following aspects:
  • ADCC is important for the efficacy of antibody therapies (e.g.,
  • ADCC may be suppressed as discussed earlier for a variety of reasons, e.g., an immunosuppressive environment, engagement of inhibitory receptors or inability of effector cells to proliferate.
  • Complement system is also important for Rituxan® (Rituximab) efficacy.
  • Rituxan® Rituximab
  • CLLs is an indolent B cell cancer
  • patients are often refractory to Rituxan® because they are either deficient in complement or because complement gets depleted soon after the start of a Rituxan® treatment (Xu et al., 2011, International Journal of Cancer 128: 2193-2201; Kennedy et al., 2004, Journal of Immunology 172 (5) 3280-3288).
  • ADCC Enhancer will be able to circumvent the problem and recruit cytotoxic T cells to the cancer cells.
  • the SUAEP technology as provided by the present invention will be useful in reducing the amounts of antibodies that need to be used for therapy and thereby minimize (a) the non-specific side effects of the antibody; and (b) reduce the chance of developing an anti-antibody response. It should be noted that even a fully human antibody has unique CDR3s that can trigger an immune response. Reducing the amount of antibody used in therapy will reduce the chance of triggering this response.
  • a fusion protein that functions as a circulating, free-associating Adapter-like ADCC Enhancer has two components: a high-affinity Fc-binding domain that couples to antibodies, and a high- affinity CD3-binding domain that engages T cells (FIG. 3).
  • the Fc-binding domain for the Adapter-like ADCC Enhancer can come from multiple sources, including:
  • FcyRl is the high affinity Fc receptor (Kd ⁇ 10 "9 M for IgGl and IgG3) present on macrophages and neutrophils and is responsible for antibody-mediated phagocytosis and mediator release.
  • FcyRI includes a glycoprotein a chain whose extracellular domain is comprised of three immunoglobulin domains that are responsible for binding to antibodies.
  • parts or all of the ectodomain of CD64 (FcyRI) is fused to a suitable CD3-binding domain to generate an Adapter-like Enhancer that mediates ADCC.
  • the Enhancer in this embodiment is syngeneic and, therefore, non- immunogenic.
  • Adapter-like ADCC Enhancer of the present invention incorporates parts or all of the ectodomain of a CD 16 (FcyRIII) variant with improved affinity to the Fc fragment of antibodies.
  • the sequence for the Fc-binding domain is generated by random mutagenesis of the binding region of FcyRIIIa and selected by using the most common CD 16 variant (F158) as benchmarking control.
  • the Fc-binding domain of the present invention incorporates an antibody fragment engineered with high-affinity for Fc (preferably human Fc).
  • the antibody fragment is an ScFv (single-chain variable fragment).
  • the fragment is a Fab (fragment antigen- binding).
  • the antibody fragment should exhibit higher Fc affinity than a benchmark receptor, e.g., CD16.
  • Methods to engineer such antibody fragments are well known to one skilled in the art, e.g., through the use of hybridomas available commercially.
  • human Fc domain is injected into lab animals (e.g., mice) over a period of time.
  • B cells isolated from the animals' spleen are fused with myeloma cells and screened for clones that produce high-affinity monoclonal antibodies against the Fc domain.
  • candidate antibodies can be humanized, deimmunized and/or converted in Fab or ScFv versions by standard methods.
  • fully human antibodies can be obtained through screening libraries (e.g. phage display, yeast or mammalian cell-based) for high affinity clones or monoclonal antibodies from animals with humanized immune systems.
  • the CD3-binding domain preferably with high affinity, can also be made from multiple sources.
  • this domain can be derived from OKT3, which is an anti-
  • the CD3-binding domain comprises the scFv portion of the OKT3 antibody, preferably, the deimmunized, humanized (dhOKT3) version.
  • novel anti-CD3 scFv can be made using methods similar to those described in Section (a)(iii) above with regard to high-affinity Fc-binding scFv.
  • the Adapter-like ADCC Enhancer is a fusion protein where the CD64 ectodomain is coupled to the dhOKT3 scFv.
  • this therapeutic can be used to enhance the efficacy of commercially available anti-cancer antibodies.
  • this therapeutic can also be used as monotherapy to enhance the efficacy of the body' s natural antibodies that are unable to clear tumors because of intrinsic low ADCC activity of a patient.
  • Rituxan® an antibody that targets CD20 implicated in lymphoma, autoimmune diseases and transplant rejection, resulting in effector cell activation, degranulation and proliferation, (2) CD8 + cytotoxic T cells, and (3) the Adapter-like ADCC Enhancer of the present invention.
  • the ADCC enhancer of the invention is used in combination with the existing therapeutic antibody such as Rituximab.
  • Target cell killing is also observed.
  • In vivo testing is performed using commercially available NOD.scid. IL2RY _/" mice which have very low T and B cells and no NK cells. Alternatively, NOD. Scid mice which have very low T and B cells and reduced NK cells are used.
  • mice are engrafted with labeled Daudi cells and tumor growth is observed and measured using any suitable imaging technique.
  • mice receiving Rituximab and immune effector cells transduced with the ADCC Enhancer of the present invention sustained periods of tumor remission, regression, or long-term non-progression are observed.
  • SK-BR-3 or MDA-MB-231 are treated with (1) CD8+ cytotoxic T cells, (2) the Adapter-like ADCC Enhancer of the present invention, and (3) Trastuzumab (trade name Herceptin®) which targets the HER2/neu implicated in breast cancers, resulting in effector cell activation, degranulation and proliferation. Target cell killing is also observed.
  • Trastuzumab trade name Herceptin®
  • In vivo anti-tumor potency of the ADCC Enhancer is observed in mice models similar to the example described immediately above.
  • ADCC Enhancer of the present invention The clinical use of the ADCC Enhancer of the present invention in autoimmunity can be tested using one of the well-established mouse models for each specific disease. For instance, antibody-mediated B cell deletion has been shown to prevent and even reverse type-1 diabetes in NOD mice. However, this effect is limited by the low affinity of the Fc receptors (Hu et al. J Clin Invest. 2007, 1 17(12): 3857-67; Xiu et al. J Immunol. 2008, 180(5):2863-75). Control mice are compared with mice receiving either anti-CD 19 or anti-CD20 antibodies alone or in combination with the ADCC Enhancer of the present invention. The mice receiving the ADCC Enhancer show delayed onset of disease or sustained reversal of symptoms.
  • ADCC Enhancers in viral infections such as HIV infection can be tested using well-established humanized mouse model where treatment with a combination of antibodies has been shown to control HIV replication ⁇ Nature, 2012, 492(7427): 118-22). Humanized mice are first generated by reconstituting
  • RAG ⁇ IL2RY "/_ mice with human fetal liver-derived CD34+ hematopoietic stem cells These mice have a completely human immune system, can be infected by HIV and do not negatively react to human antibodies. Infected control mice are compared with mice receiving either neutralizing antibody cocktail alone or in combination with either human immune effector cells along with the Adapter-like ADCC Enhancer of the present invention. The mice receiving the ADCC Enhancer show sustained reduction in viremia and recovery in T cell numbers.
  • An alternate model system to test the clinical efficacy of the ADCC Enhancer is the simian-human immunodeficiency virus (SHIV)-infected infant rhesus macaque model where neutralizing antibodies have been shown to prevent rapid onset of the disease (Jaworski et al. J Virol. 2013, 87(19): 10447-59).
  • Infected control macaques are compared with those receiving either neutralizing antibody cocktail alone or in combination with the Adapter-like ADCC Enhancer of the present invention.
  • the macaques receiving the ADCC enhancer similarly show sustained reduction in viremia and recovery in T cell numbers.
  • DNA and RNA constructs that encode ADCC Enhancing system of the present invention may be formulated for administration to a subject using techniques known to the skilled artisan.
  • Formulations comprising DNA and RNA constructs that encode the ADCC Enhancing system may include pharmaceutically acceptable excipient(s). Excipients included in the formulations will have different purposes depending, for example, on the kind of gene construct or effector cells used, and the mode of administration.
  • excipients include, without limitation: saline, buffered saline, dextrose, water-for-infection, glycerol, ethanol, and combinations thereof, stabilizing agents, solubilizing agents and surfactants, buffers and preservatives, tonicity agents, bulking agents, and lubricating agents.
  • a pharmaceutical formulation of the Adapter-like ADCC Enhancer of the invention is administered into the patient.
  • Exemplary administration modes include, but are not limited to, intravenous injection.
  • Other modes include, without limitation, intratumoral, intradermal, subcutaneous (s.c, s.q., sub-Q, Hypo), intramuscular (i.m.), intraperitoneal (i.p.), intra-arterial,
  • Any known device useful for parenteral injection or infusion of the formulations can be used to effect such
  • the terms “treat”, “treating”, and “treatment” have their ordinary and customary meanings, and include one or more of: blocking, ameliorating, or decreasing in severity and/or frequency a symptom of a disease (e.g., cancer) in a subject, and/or inhibiting the growth, division, spread, or proliferation of cancer cells, or progression of cancer (e.g., emergence of new tumors) in a subject.
  • Treatment means blocking, ameliorating, decreasing, or inhibiting by about 1% to about 100% versus a subject in which the methods of the present invention have not been practiced.
  • the blocking, ameliorating, decreasing, or inhibiting is about 100%, 99%, 98%, 97%, 96%, 95%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5% or 1% versus a subject in which the methods of the present invention have not been practiced.
  • the clinical potency, both as a therapeutic and a prophylactic, of the ADCC Enhancer of the present invention may be optionally enhanced through the use of dendritic cells (DCs).
  • DCs dendritic cells
  • T-helper cells which in turn, regulate immune effectors including CTLs, B cells, macrophages, eosinophils and NK cells.
  • CTLs CTLs
  • B cells B cells
  • macrophages eosinophils
  • NK cells NK cells
  • DCs are first isolated from the subject patient, and then primed ex vivo through incubation with a source of target antigen(s), e.g., certain tumors-associated antigens or other surface markers of a disease which can be from the subject patient or a foreign source.
  • target antigen(s) e.g., certain tumors-associated antigens or other surface markers of a disease which can be from the subject patient or a foreign source.
  • These DCs are eventually infused back into the patient prior to treatment by autologous CTL and/or other effector cells transfected with the ADCC Enhancing system of the present invention or by formulations comprising DNA and RNA constructs that encode the ADCC Enhancing system. This provides a model of enhanced treatment as well as vaccine using the ADCC Enhancer with the help of DCs.
  • the invention also provides a kit comprising one or more containers filled with quantities of gene constructs encoding the Adapter-like ADCC Enhancer, with pharmaceutically acceptable excipients.
  • the kit may also include instructions for use.
  • Associated with the kit may further be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
  • ADCC Enhancers i.e., fusion proteins with a high-affinity Fc-binding domain linked to a high-affinity CD3 -binding domain were developed and tested.
  • Enhancer or, a soluble, free-associating, circulating T-cell adapter
  • Fc-binding ectodomain of CD64 is fused to a de-immunized and humanized scFv version of Orthoclone OKT3 (also known as Muromonab-CD3), which is an anti-CD3 antibody.
  • Orthoclone OKT3 also known as Muromonab-CD3
  • Fc-binding domains e.g., based on the ectodomains, i.e., extracellular domains, of other Fc receptors (e.g., CD32 and CD 16), can also be used in other embodiments of the invention.
  • CD64 i.e., FcyRI
  • FcyRI has about a 100- to a 1000-fold higher affinity for the Fc region of antibodies than CD 16, making CD64's ectodomain, the part of CD64 that is responsible for antibody binding, the preferred candidate for the Fc-binding domain in the fusion protein.
  • the junctions of the protein fusion were decided by the exon boundaries of the original protein (see FIG. 2).
  • the CD64 domain thus derived for the fusion protein included two exons coding for the secretory signal followed by three exons coding for the ectodomain and is shown in FIG. 3 as SEQ ID NO: l .
  • the secretory signal sequence does not have to come from CD64, however, and can be replaced by other suitable secretory signal sequences.
  • the junctions of the protein fusion are based on the predicted amino acid boundary between the ectodomain and the transmembrane domain of the original protein. Compared to the exon-based fusion, this approach would add to the fusion protein portions of the linker sequence between the two original domains for instance.
  • the rest of the fusion protein (SEQ ID NO:2), including two spacer sequences and the OKT3 sequence is shown in FIG. 4.
  • the OKT3 is originally derived from mouse cells, but has been humanized, i.e., converted or mutated to be more like an antibody from humans by many groups. Humanizing an antibody or antibody fragment is a standard procedure known to one of ordinary skills in the art.
  • the complete sequence (SEQ ID NO:3) of the Adapter-like ADCC Enhancer where the extracellular portion of CD64 was fused with a de-immunized and humanized OKT3 (dhOKT3) through a flexible serine-glycine linker is shown in FIG. 5.
  • other agonistic anti-CD3 sequences such as a humanized TR66, can be used.
  • the CD64-dhOKT3 fusion protein was back translated and sequence-optimized to generate the DNA sequence (SEQ ID NO:4) shown in the figure.
  • the optimization relied on a combination of choosing codons for individual amino acids that appear in humans more frequently as well as removing repeat regions as well as regions that could potentially form secondary structures.
  • Alternate embodiments of the invention include adding a tag (e.g., Myc or
  • the synthetic gene for the CD64-dhOKT3 fusion protein was chemically synthesized and cloned into a mammalian expression vector.
  • the vector pVITR02-MCS commercially available from Invivogen®, was used, but there are many common vectors that can serve the same function.
  • the recombinant expression vector was transfected into Expi293 cells (commercially available from Thermo Fisher Scientific) following the manufacturer's instructions. The resulting cell line produced soluble secreted protein (FIGS. 7 and 8). Briefly, Expi293 cells were grown in Expi293
  • Synthesized ADCC-enhancers 1 and 2 (FIG. 7) were added to the culture 16-20 hours post-transfection and the supernatant was collected 2 to 7 days post-transfection.
  • other expression systems e.g., CHO cells
  • the expression cassette can be stably integrated into the genome of the cell line to generate a stable derivative that produces the fusion protein.
  • the ADCC-enhancer protein was affinity-purified using commonly known methods such as commercially available IgG Sepharose column (GE Healthcare Life Sciences) (FIG. 8). Briefly, supernatant from transfected cells was loaded onto the column packed with Sepharose beads crosslinked with human IgG. The column was then washed with a neutral pH buffer and a step-wise gradient of lower pH citrate-phosphate buffer. The ADCC-enhancer protein was eluted at low pH ( ⁇ pH 3) and immediately neutralized in 1M TrisHCl (pH 7.4). The buffer was exchanged by dialysis or ultrafiltration.
  • Protein L binds to the kappa chain of many species including that of an scFv, such as the OKT3 portion of the fusion protein here.
  • Other standard methods for purifying an untagged protein e.g., ion exchange, size exclusion, and so on, can also be used either alone or in combination in the present invention.
  • the fusion protein can be tagged with standard tags for easy purification using appropriate affinity columns. These steps can also be used in tandem to yield higher purity protein.
  • CD64-antiCD3 fusion protein to bind Fc and CD3 can be tested either directly using the supernatant or the purified protein in several ways.
  • Jurkat cells can be used to test such affinity, as Jurkat cells are T lymphocyte cells expressing CD3.
  • 2 x 10 5 Jurkat cells were washed in PBS and incubated for 30 minutes at 4°C in 50 ⁇ of culture supernatant (from Expi293 cells that had been transfected for several days with the expression vector) or purified fusion proteins.
  • the cells were washed twice with PBS and then bound ADCC enhancer was detected using commercially available fluorescently tagged anti-CD64 antibody (FIG. 10).
  • FIG. 11 titration of binding to Jurkat cells was conducted and results show correlation between binding and the concentration of the Enhancer.
  • binding affinity can also be detected using a fluorescently tagged anti-tag antibody.
  • This approach can also be used to detect binding of the CD64 domain by rituximab-coated CD20 + Daudi cells (see FIG. 12). Briefly, 10 6
  • Daudi cells were harvested, washed with PBS and incubated for 30 minutes at 4 C with 0.1 ⁇ g/ml of rituximab (an antibody against CD20, also known as Rituxan. MabThera and Zytux). Cells were again washed in PBS and then incubated with the supernatant or purified protein as described above (FIG. 13).
  • rituximab an antibody against CD20, also known as Rituxan. MabThera and Zytux.
  • FIG. 14 titration of binding to Daudi cells was conducted and results show very correlation between binding and the concentration of the Enhancer.
  • the Fc- or antibody -binding by the Adapter-like ADCC Enhancer appear to be about 30 times stronger than CD3 -binding from the other end of the Enhancer.
  • heterologous aggregation is examined between rituximab-coated Daudi and Jurkat cells in co-culture systems as indication of binding affinities.
  • Daudi and Jurkat cells are respectively labeled with live cell stains such as CFSE or Cell Trace Far Red using standard methods and/or engineered to express fluorescent proteins such as GFP.
  • the cells are then co-incubated with the Rituximab and the soluble ADCC Enhancer of the present invention.
  • FACS data is examined for doublets that are positive for both colors.
  • the choices of cell lines in embodiments described herein are not limited to Jurkat and Daudi cells— the present invention contemplates the use of a variety of cell lines or primary cells in combination with appropriate antibodies.
  • the ability of the CD64-antiCD3 fusion protein to bind Fc and CD3 can also be tested by surface plasmon resonance, or other standard biochemical or cell-based assays.
  • Naive primary CD8 + T cells were isolated from donated blood using standard procedure, e.g., using RosetteSep CD8 T Cell Enrichment Kit (Stem Cell Technology) followed by expansion with anti-CD3/CD28.
  • similar experiments can be conducted with total T cells or PBMCs.
  • T cell proliferation can be measured by flow cytometry or other traditional methods e.g. thymidine incorporation, CFSE dilution, etc.
  • Activation can be measured by detecting a variety of known activation markers e.g. HLA-DR, CD25, CD69, etc.
  • the Enhancer might work by itself but additional experiments were done with or without:
  • Lysosomal-associated membrane protein- 1 (LAMP-1 or CD 107a) has been described as a marker of CD8+ T- cell and NK cell degranulation of lytic granules following stimulation. Therefore, in the co-culture experiments described above, the level of CD107a+ T cells can be analyzed as a measure of degranulation through flow cytometry.
  • FIGS 15 and 16 show that the Enhancer of the invention was able to kill much of the CD20 + Daudi cell population, in the presence of Rituxan, by recruiting T cell to affect ADCC.
  • data presented in FIG. 19 shows that the Enhancer of the invention triggers the killing capacity of Herceptin, an antibody designed against HER2 receptors on breast cancer cells, over SK-BR3 breast cancer cells presumably as T cells were recruited by the Enhancer to enhance ADCC.
  • CD33+ AML lines e.g. HL-60, MOLM-13 and THP- 1 treated with anti-CD33 antibody (WM-53);
  • CD19+ lines e.g. NALM-6 and MEC- 1 treated with anti-CD19 antibody (HIB19); and
  • EpCAM+ lines e.g. SW480 treated with anti-EpCAM antibody (HEA-125).
  • Nivolumab anti-PDl antibody
  • HEK-293T cells Human Embryonic Kidney cells expressing large T antigen
  • CD8+ T cells CD8+ T cells
  • Enhancer of the invention The parental, unmodified HEK-293T cells ("293T") as well as an IgG4 control were included as controls.
  • Nivolumab was developed as an IgG4 antibody so as to not have any ADCC activity. However, subsequent experiments have shown that ADCC and PD1 antibodies might work better together.
  • Adapter-like ADCC Enhancer with antibodies, such as Rituxan and Herceptin, to enhance their function, to reduce antibody dosage, reduce side effects and anti-antibody response.
  • Rituxan or Rituximab has produced mixed results in treating autoimmune patients: it works well in RA but only marginally in SLE.
  • macrophage-mediated B cell depletion is saturated in SLE patients. Redirecting B cell killing to T cells using the ADCC Enhancer as a T-cell Adapter will circumvent this problem.
  • Enhancer can be used in patients with low affinity version of CD16 (158F), or patients where ADCC/CDC is suppressed somehow, e.g., chronic lymphocytic leukemia (CLL) patients and other patients undergoing cancer treatment.
  • CLL chronic lymphocytic leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne de nouvelles technologies de synthèse d'ADCC basées sur la biologie qui améliorent ou permettent des réponses ADCC, par exemple, à travers une protéine activatrice ADCC universelle soluble rationnellement conçue (SUAEP) dans laquelle un domaine de liaison CD3 de haute affinité est condensé à un domaine de liaison Fc de haute affinité. La technologie SUAEP peut être utilisée pour prévenir ou traiter les cancers, les maladies infectieuses, inflammatoires ou auto-immunes, et d'autres maladies dans lesquelles l'élimination de cellules malades est souhaitable.
EP15867381.4A 2014-12-08 2015-12-08 Gène de fusion synthétique universel soluble améliorant l'adcc et technologie peptidique et son utilisation Active EP3230311B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462089097P 2014-12-08 2014-12-08
US201562200557P 2015-08-03 2015-08-03
PCT/US2015/064572 WO2016094456A1 (fr) 2014-12-08 2015-12-08 Gène de fusion synthétique universel soluble améliorant l'adcc et technologie peptidique et son utilisation

Publications (3)

Publication Number Publication Date
EP3230311A1 true EP3230311A1 (fr) 2017-10-18
EP3230311A4 EP3230311A4 (fr) 2018-05-30
EP3230311B1 EP3230311B1 (fr) 2022-01-26

Family

ID=56108081

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15867381.4A Active EP3230311B1 (fr) 2014-12-08 2015-12-08 Gène de fusion synthétique universel soluble améliorant l'adcc et technologie peptidique et son utilisation

Country Status (11)

Country Link
US (2) US20170362299A1 (fr)
EP (1) EP3230311B1 (fr)
JP (2) JP7095992B2 (fr)
KR (1) KR102654033B1 (fr)
CN (1) CN107108718B (fr)
AU (1) AU2015360642B2 (fr)
CA (1) CA2968987C (fr)
NZ (1) NZ732073A (fr)
RU (1) RU2725807C2 (fr)
SG (1) SG11201704124YA (fr)
WO (1) WO2016094456A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY184154A (en) 2013-12-12 2021-03-23 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
CN112512573A (zh) * 2018-05-23 2021-03-16 百提威生技股份有限公司 双特异性t细胞衔接蛋白及其用途
WO2020232247A1 (fr) 2019-05-14 2020-11-19 Provention Bio, Inc. Procédés et compositions pour la prévention du diabète de type 1
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
CN115803037A (zh) * 2020-06-30 2023-03-14 盖亚生物制药有限公司 稳定nk细胞与抗体的结合的方法及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
IL101147A (en) * 1991-03-07 2004-06-20 Gen Hospital Corp Change of direction of cellular immunity by chimera receptors
ES2176574T3 (es) * 1996-09-03 2002-12-01 Gsf Forschungszentrum Umwelt Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral.
CN100409898C (zh) * 1998-08-11 2008-08-13 拜奥根Idec公司 包括施用抗-cd20抗体的b-细胞淋巴瘤联合疗法
CN101712722A (zh) * 2000-12-07 2010-05-26 伊莱利利公司 Glp-1融合蛋白
IL158969A0 (en) * 2001-06-01 2004-05-12 Cornell Res Foundation Inc Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2004076621A2 (fr) * 2003-02-27 2004-09-10 Yeda Research And Development Co. Ltd. Molecules d'acide nucleique, polypeptides, anticorps et compositions les contenant utiles dans le traitement et la detection de l'infection imputable au virus de la grippe
EP1658095A4 (fr) * 2003-06-02 2006-06-14 Alexion Pharma Inc Anticorps anti-cd3 desimmunise
ES2358427T3 (es) * 2003-10-16 2011-05-10 Micromet Ag Elementos de unión a cd-3 desinmunizados multiespecíficos.
EP1716178B1 (fr) * 2004-02-16 2010-08-11 Micromet AG Molecules de liaison moins immunogenes
US20080003225A1 (en) 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
WO2008091682A2 (fr) * 2007-01-23 2008-07-31 Zymogenetics, Inc. FCγRIA SOLUBLE ET MÉTHODES ASSOCIÉES
US8043621B2 (en) * 2007-05-10 2011-10-25 Ramot At Tel Aviv University Ltd. Recombinant fusion protein and polynucleotide construct for immunotoxin production
WO2011085178A1 (fr) * 2010-01-11 2011-07-14 Trustees Of Dartmouth College Protéine de fusion monomérique bispécifique
BR112013016235B1 (pt) * 2010-12-22 2020-03-31 Cephalon Australia Pty Ltd Anticorpo isolado, uso de um anticorpo, ácido nucleico, célula transformada e composição farmacêutica
CN104066845A (zh) * 2011-12-15 2014-09-24 皇家学术促进会/麦吉尔大学 可溶性IGF受体Fc融合蛋白和其用途
WO2013128027A1 (fr) * 2012-03-01 2013-09-06 Amgen Research (Munich) Gmbh Molécules de liaison à un polypeptide à longue durée de vie

Also Published As

Publication number Publication date
EP3230311A4 (fr) 2018-05-30
AU2015360642B2 (en) 2019-04-04
SG11201704124YA (en) 2017-06-29
RU2017124141A3 (fr) 2019-06-19
CN107108718B (zh) 2022-07-22
US20170362299A1 (en) 2017-12-21
EP3230311B1 (fr) 2022-01-26
AU2015360642A1 (en) 2017-06-08
WO2016094456A1 (fr) 2016-06-16
CN107108718A (zh) 2017-08-29
JP2018502068A (ja) 2018-01-25
US20220235115A1 (en) 2022-07-28
NZ732073A (en) 2019-04-26
JP2021035994A (ja) 2021-03-04
RU2017124141A (ru) 2019-01-10
JP7095992B2 (ja) 2022-07-05
KR20170089003A (ko) 2017-08-02
CA2968987A1 (fr) 2016-06-16
KR102654033B1 (ko) 2024-04-02
RU2725807C2 (ru) 2020-07-06
CA2968987C (fr) 2022-05-10

Similar Documents

Publication Publication Date Title
US20220235115A1 (en) Soluble Universal ADCC-Enhancing Synthetic Fusion Gene and Peptide Technology and Its Use Thereof
US20190161553A1 (en) Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides
US9540442B2 (en) Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
JP6205363B2 (ja) ハイブリッド定常領域
EP3875484A1 (fr) Anticorps ciblant cll1 et son utilisation
US11667693B2 (en) Synthetic biology-based ADCC technology
WO2023056429A1 (fr) Anticorps anti-nmdar2b, conjugués anticorps-médicament, et récepteurs antigéniques chimériques, et compositions et méthodes d'utilisation
JP2022510634A (ja) 除去レジメンに抵抗性の遺伝的に改変されたｈｓｐｃ
WO2017177217A2 (fr) Récepteurs chimériques et utilisations de ceux-ci en thérapie immunitaire
WO2023093811A1 (fr) Combinaison d'une cellule de récepteur antigénique chimérique de type à régulation de commutation moléculaire et d'un anticorps, et son utilisation
WO2022038411A1 (fr) Région fc modifiée non naturelle humaine d'igg se liant spécifiquement à un récepteur fc modifié non naturel
WO2024140836A1 (fr) Combinaison d'une protéine de fusion ciblant un ligand nkg2d et d'une cellule réceptrice d'antigène chimérique, et son utilisation
US20240216432A1 (en) Anti-flt3 antibodies, cars, car t cells and methods of use
CN118252923A (en) Combination of fusion proteins targeting NKG2D ligands with chimeric antigen receptor cells and uses thereof
CN116847863A (zh) 抗人cd22的单克隆抗体及其用途
EP4388008A1 (fr) Anticorps anti-flt3, car, cellules car-t et procédés d'utilisation
CN118317789A (en) P329G antibody targeting BCMA and combination and application of P329G antibody and chimeric antigen receptor cell

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170605

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20180426

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 19/00 20060101ALI20180420BHEP

Ipc: A61K 39/00 20060101ALI20180420BHEP

Ipc: C07K 14/735 20060101AFI20180420BHEP

Ipc: A61K 38/00 20060101ALI20180420BHEP

Ipc: C07K 16/28 20060101ALI20180420BHEP

Ipc: C07K 16/46 20060101ALI20180420BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190307

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/735 20060101AFI20210524BHEP

Ipc: C07K 16/46 20060101ALI20210524BHEP

Ipc: C07K 19/00 20060101ALI20210524BHEP

Ipc: A61K 38/00 20060101ALI20210524BHEP

Ipc: C07K 16/28 20060101ALI20210524BHEP

Ipc: A61K 39/00 20060101ALI20210524BHEP

Ipc: A61P 35/00 20060101ALN20210524BHEP

INTG Intention to grant announced

Effective date: 20210630

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1465234

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015076726

Country of ref document: DE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20220126

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1465234

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220526

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220426

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220426

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220427

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220526

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015076726

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20221027

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20221231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221231

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221208

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221231

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231202

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20231121

Year of fee payment: 9

Ref country code: DE

Payment date: 20231214

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20151208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220126